HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joseph M Metzger Selected Research

bombesin receptor subtype 3

5/2012The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
12/2011Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
11/2011Bombesin receptor subtype-3 (BRS-3) regulates glucose-stimulated insulin secretion in pancreatic islets across multiple species.
2/2011Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
11/2010Body temperature as a mouse pharmacodynamic response to bombesin receptor subtype-3 agonists and other potential obesity treatments.
4/2010Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
2/2010Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joseph M Metzger Research Topics

Disease

16Cardiomyopathies (Cardiomyopathy)
02/2020 - 11/2002
14Obesity
05/2012 - 09/2006
12Heart Failure
01/2021 - 02/2005
10Heart Diseases (Heart Disease)
04/2013 - 09/2002
9Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
05/2020 - 08/2005
7Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
05/2008 - 01/2002
6Hypoxia (Hypoxemia)
12/2018 - 09/2007
6Ischemia
06/2016 - 02/2006
6Body Weight (Weight, Body)
12/2011 - 08/2005
4Fibrosis (Cirrhosis)
02/2020 - 04/2010
4Muscular Dystrophies (Muscular Dystrophy)
01/2017 - 08/2005
4Hemorrhage
09/2016 - 06/2015
3Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
02/2020 - 05/2008
3Hypertrophy
05/2017 - 08/2002
3Contracture
08/2015 - 08/2005
3Restrictive Cardiomyopathy
09/2014 - 05/2007
2Diastolic Heart Failure
01/2019 - 10/2016
2Reperfusion Injury
06/2016 - 02/2015
2Thrombosis (Thrombus)
02/2016 - 06/2015
2Hypothermia
02/2015 - 01/2008
2Type 2 Diabetes Mellitus (MODY)
02/2012 - 08/2005
2Weight Loss (Weight Reduction)
02/2011 - 11/2010
2Weight Gain
06/2009 - 01/2008
2Acidosis
05/2009 - 02/2006
1Neoplasms (Cancer)
12/2021
1Cachexia
12/2021
1Disease Progression
02/2020
1Wounds and Injuries (Trauma)
01/2020
1Anemia
12/2018
1Vascular Remodeling
05/2017
1Pulmonary Arterial Hypertension
05/2017
1Bartter Syndrome (Syndrome, Bartter)
10/2016
1ST Elevation Myocardial Infarction
06/2016
1Infarction (Infarctions)
06/2016
1Alkalosis
01/2016
1Hemophilia B (Haemophilia B)
06/2015
1Neurologic Manifestations (Neurological Manifestations)
02/2015
1Ventricular Fibrillation
02/2015
1Heart Arrest (Cardiac Arrest)
02/2015
1Breast Neoplasms (Breast Cancer)
01/2013
1Insulin Resistance
02/2012

Drug/Important Bio-Agent (IBA)

14Proteins (Proteins, Gene)FDA Link
02/2020 - 08/2002
12CalciumIBA
12/2021 - 09/2002
12DystrophinIBA
05/2020 - 08/2005
11Troponin IIBA
06/2016 - 09/2002
7bombesin receptor subtype 3IBA
05/2012 - 02/2010
6Bombesin Receptors (Bombesin Receptor)IBA
03/2012 - 04/2010
5Poloxamer (Poloxamer 407)IBA
01/2020 - 08/2005
5Protein Isoforms (Isoforms)IBA
07/2009 - 09/2002
4Histidine (L-Histidine)FDA Link
09/2014 - 09/2007
3TropomyosinIBA
05/2004 - 01/2002
2junctophilinIBA
05/2017 - 01/2016
2BuffersIBA
10/2016 - 05/2008
2ParvalbuminsIBA
10/2016 - 05/2004
2Potassium Channels (Potassium Channel)IBA
10/2016 - 03/2007
2Insulin (Novolin)FDA Link
02/2012 - 08/2005
2Sarcoglycans (beta Sarcoglycan)IBA
01/2012 - 09/2011
2Glucose (Dextrose)FDA LinkGeneric
07/2011 - 08/2005
21,1,1- trifluoro- 2- (4- (1H- pyrazol- 1- yl)phenyl)- 3- (4- ((1- (trifluoromethyl)cyclopropyl)methyl)- 1H- imidazol- 2- yl)propan- 2- olIBA
02/2011 - 01/2011
2Dihydrotachysterol (AT 10)IBA
01/2008 - 09/2006
1Cysteine (L-Cysteine)FDA Link
01/2021
1Glycoproteins (Glycoprotein)IBA
02/2020
1polypropylene glycol (poly(propylene oxide))IBA
01/2020
1PEO-PPO-PEOIBA
01/2020
1Ethylene Oxide (Oxirane)IBA
01/2020
1Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
12/2018
1Evans Blue (Blue, Evans)FDA Link
12/2018
1Calcium-Transporting ATPases (Ca2+ ATPase)IBA
12/2018
1phospholambanIBA
12/2018
1Coloring Agents (Dyes)IBA
12/2018
1ColchicineFDA LinkGeneric
05/2017
1Biological ProductsIBA
01/2017
1MK-7145IBA
10/2016
1PAR-1 ReceptorIBA
09/2016
1EnzymesIBA
02/2016
1apixabanIBA
02/2016
1AnticoagulantsIBA
02/2016
1W 7 (W7)IBA
01/2016
1Factor XII (Hageman Factor)IBA
12/2015
1GlycogenIBA
08/2015
1Adenosine Triphosphate (ATP)IBA
08/2015
1Peptides (Polypeptides)IBA
07/2015
1Peptide Hydrolases (Proteases)FDA Link
07/2015
1Messenger RNA (mRNA)IBA
06/2015
1Small Interfering RNA (siRNA)IBA
06/2015
1Factor IX (Coagulation Factor IX)FDA LinkGeneric
06/2015
1Blood Coagulation Factors (Coagulation Factor)IBA
06/2015
1Epinephrine (Adrenaline)FDA LinkGeneric
02/2015
1Sevoflurane (Ultane)FDA LinkGeneric
02/2015
1TamoxifenFDA LinkGeneric
01/2013
1Selective Estrogen Receptor Modulators (SERM)IBA
01/2013
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
05/2012
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
02/2012
1fibroblast growth factor 21IBA
02/2012

Therapy/Procedure

16Therapeutics
02/2020 - 11/2002
3Oral Administration
04/2010 - 09/2006
1Catheters
06/2016
1Cardiopulmonary Resuscitation (CPR)
02/2015
1Resuscitation
02/2015
1Ischemic Postconditioning
02/2015